CTOs on the Move

YM BioSciences

www.ymbiosciences.com

 
YM BioSciences Inc. is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.ymbiosciences.com
  • Orbitor Drive BLDG 11 STE 400 5045 Mississauga Rd
    Mississauga, ON CAN L5M 4Y1
  • Phone: 905.629.9761

Executives

Name Title Contact Details

Similar Companies

BioMedix

Previously Mr. Lerner has served as Vice President of Engineering and Technology for both Image Sensing Systems, Inc. and Telex Communications, Inc.

Covance the development services company

Covance the development services company is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Celladon

Celladon is a privately held biotechnology company founded with the goal of developing molecular therapies for cardiovascular diseases. Breakthroughs in the basic understanding of the cardiovascular networks combined with powerful new technologies have provided the foundation for new, rational, and technologically sophisticated approaches to cardiovascular treatments. Our first product candidate is designed to target the key enzyme deficiency in advanced heart failure which regulates calcium cycling and contractility in heart muscle cells.

Armata Pharmaceuticals

Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology.

Genprex

Genprex (Nasdaq: GNPX) is a clinical-stage gene therapy company focused on developing life-changing technologies for patients with cancer and diabetes. Genprex`s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches for patients with cancer and other serious diseases.